Amgen Announces 2017 Fourth Quarter Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks weigh on markets
- Oil jumps around 5% to two-week high after Trump warns of more attacks on Iran
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Amgen (AMGN) PT Lowered to $193 at Morgan Stanley Following 3Q
October 26, 2017 9:25 AM EDTMorgan Stanley lowered its price target on Amgen (NASDAQ: AMGN) to $193.00 (from $196.00) while maintaining a Overweight rating following the company's 3Q release. Total revenues were slightly above ($5.77B vs. $5.74B cons), as were COGS (+$10M) and SG&A (+$20M), with R&D... More
